Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.
To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.
| Study Number Sort descending | Lead Group | Study Title | CIRB | Study Status | |
|---|---|---|---|---|---|
| GOG-0201 | GOG | Treatment of Patients with Stage IB2 Carcinoma of the Cervix: A Randomized Comparison of Radical Hysterectomy and Tailored Chemoradiation VERSUS Primary Chemoradiation | Adult CIRB - Late Phase Emphasis | Completed | |
| GOG-0204 | GOG | A Randomized Phase III Trial of Paclitaxel Plus Cisplatin Versus Vinorelbine Plus Cisplatin Versus Gemcitabine Plus Cisplatin Versus Topotecan Plus Cisplatin in Stage IVB; Recurrent; or Persistent Carcinoma of the Cervix | Adult CIRB - Late Phase Emphasis | Completed | |
| GOG-0209 | GOG | Randomized Phase III Trial of Doxorubicin/Cisplatin/Paclitaxel and G-CSF Versus Carboplatin/Paclitaxel in Patients with Stage III & IV or Recurrent Endometrial Cancer | Adult CIRB - Late Phase Emphasis | Completed | |
| GOG-0212 | GOG | A Randomized Phase III Trial of Maintenance Chemotherapy Comparing 12 Monthly Cycles of Single Agent Paclitaxel or CT-2103 (IND# 70177) Versus No Treatment Until Documented Relapse in Women With Advanced Ovarian; Primary Peritoneal; or Fallopian Tube Cancer who Achieve a Complete Clinical Response to Primary Platinum/Taxane Chemotherapy | Adult CIRB - Late Phase Emphasis | Completed | |
| GOG-0213 | GOG | A Phase III Randomized Controlled Clinical Trial of Carboplatin and Paclitaxel (Or Gemcitabine) Alone or in Combination with Bevacizumab (NSC #704865; IND #113912) followed by Bevacizumab and Secondary Cytoreductive Surgery in Platinum-Sensitive; Recurrent Ovarian; Peritoneal Primary and Fallopian Tube Cancer. NCI-Supplied Agents: Bevacizumab (NSC #704865; IND #113912)(12/19/2011) (10/01/12) NCT# 00565851 | Adult CIRB - Late Phase Emphasis | Available to Open | |
| GOG-0218 | GOG | A Phase III Trial of Carboplatin and Paclitaxel Plus Placebo Versus Carboplatin and Paclitaxel Plus Concurrent Bevacizumab (NSC #704865; IND #113912) Followed by Placebo; Versus Carboplatin and Paclitaxel Plus Concurrent and Extended Bevacizumab; in Women With Newly Diagnosed; Previously Untreated; Stage III or IV; Epithelial Ovarian; Primary Peritoneal or Fallopian Tube Cancer | Adult CIRB - Late Phase Emphasis | Completed | |
| GOG-0219 | GOG | A Phase III; Randomized Trial of Weekly Cisplatin and Radiation Versus Cisplatin and Tirapazamine and Radiation in Stage IB2; IIA; IIB; IIIB; and IVA Cervical Carcinoma Limited to the Pelvis | Adult CIRB - Late Phase Emphasis | Completed | |
| GOG-0240 | GOG | A Randomized Phase III Trial of Cisplatin plus Paclitaxel with and without NCI-Supplied Bevacizumab (NSC #704865; IND #113912) Versus the Non-Platinum Doublet; Topotecan Plus Paclitaxel; with and without NCI-Supplied Bevacizumab; in Stage IVB; Recurrent or Persistent Carcinoma of the Cervix | Adult CIRB - Late Phase Emphasis | Completed | |
| GOG-0241 | GOG | A GCIG Intergroup Multicenter Phase III Trial of Open Label Carboplatin and Paclitaxel +/- NCI-Supplied Agent: Bevacizumab (NSC #704865; IND #113912) Compared With Oxaliplatin and Capecitabine +/- Bevacizumab as First Line Chemotherapy in Patients with Mucinous Epithelial Ovarian or Fallopian Tube Cancer (MEOC) | Adult CIRB - Late Phase Emphasis | Completed | |
| GOG-0249 | GOG | A Phase III Trial of Pelvic Radiation Therapy Versus Vaginal Cuff Brachytherapy Followed By Paclitaxel/Carboplatin Chemotherapy in Patients with High Risk; Early Stage Endometrial Carcinoma | Adult CIRB - Late Phase Emphasis | Completed |